Evaluation of glucose control when a new strategy of increased carbohydrate supply is implemented during prolonged physical exercise in type 1 diabetes

2015 ◽  
Vol 115 (12) ◽  
pp. 2599-2607 ◽  
Author(s):  
Peter Adolfsson ◽  
Stig Mattsson ◽  
Johan Jendle
Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 983-P
Author(s):  
SUE A. BROWN ◽  
BRUCE W. BODE ◽  
CAROL J. LEVY ◽  
GREGORY P. FORLENZA ◽  
BRUCE A. BUCKINGHAM ◽  
...  

2018 ◽  
Vol 66 (3) ◽  

The prevalence of obesity is increasing world-wide. Obesity is associated with a plethora of metabolic and clinical constraints, which result in a higher risk for the development of cardiovascular complications and metabolic disease, particularly insulin resistance and type 2 diabetes. Obesity is an acknowledged determinant of glycemic control in patients with type 1 diabetes and accounts for the majority of premature death due to cardiovascular events. Physical exercise is generally recommended in patients with diabetes in order to prevent the development of or reduce existing obesity, as adopted by every international treatment guideline so far. Regular physical exercise has a beneficial impact on body composition, cardiovascular integrity, insulin sensitivity and quality of life. However, only a minority of patients participates in regular physical exercise, due to individual or ­disease-related barriers. In type 2 diabetes, there is robust evidence for beneficial effects of physical exercise on glycemic control, cardiovascular health and the development of diabetes-related long-term complications. In type 1 diabetes and patients treated with insulin, a higher risk for exercise-­related hypoglycemia has to be considered, which requires certain prerequisites and adequate adaptions of insulin ­dosing. Current treatment guidelines do only incompletely address the development of exercise-related hypoglycemia. However, every patient with diabetes should participate in regular physical exercise in order to support and enable ­sufficient treatment and optimal glycemic control.


2019 ◽  
Author(s):  
Arkadiusz Michalak ◽  
Konrad Pagacz ◽  
Wojciech Młynarski ◽  
Agnieszka Szadkowska ◽  
Wojciech Fendler

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Chun-xiu Gong ◽  
Li-ya Wei ◽  
Di Wu ◽  
Bing-yan Cao ◽  
Xi Meng ◽  
...  

Aims. To determine whether multiple daily injections (MDIs) or continuous subcutaneous insulin infusion (CSII) contributes to better glucose control in children with different type 1 diabetes duration.Methods. Subjects were grouped according to early (≤1 year after disease onset; 1A) or late (1–3 years after onset; 2A) MDIs/CSII treatment initiation. Corresponding control groups (1B, 2B) received insulin injections twice daily.Results. HbA1c levels were consistently lower in group 1A than in group 1B (6 months (T2): 7.37% versus 8.21%; 12 months (T3): 7.61% versus 8.41%; 24/36 months (T4/T5): 7.61% versus 8.72%; allP<0.05), but were lower in group 2A than in group 2B only at T2 (8.36% versus 9.19%;P=0.04). Levels were lower in group 1A than in group 2A when disease duration was matched (7.61% versus 8.49%;P<0.05). Logistic regression revealed no correlation between HbA1c level and MDIs/CSII therapy. HbA1c levels were only negatively related to insulin dosage.Conclusions. Blood glucose control was better in patients receiving MDIs/CSII than in those receiving conventional treatment. Early MDIs/CSII initiation resulted in prolonged maintenance of low HbA1c levels compared with late initiation. MDIs/CSII therapy should be combined with comprehensive management.


2000 ◽  
Vol 50 ◽  
pp. 220-221
Author(s):  
M Pein ◽  
J Deibler ◽  
P Roach ◽  
J Woodworth ◽  
U Gudat ◽  
...  

1990 ◽  
Vol 7 (8) ◽  
pp. 695-699 ◽  
Author(s):  
B.H.R. Wolffenbuttel ◽  
B.M. Ouwerkerk ◽  
B.F.E. Veldhuyzen ◽  
P.H.L.M. Geelhoed-Duijvestijn ◽  
G. Jakobsen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document